tirzepatide side effects heart Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology 💊 New research in obesity

Trng i hc Bun Ma Thut c thnh lp theo Quyt nh 1450/Q TTg ngy 19 thng 08 nm 2014 ca Th tng chnh ph

This dual GLP-1/GIP receptor agonist suppresses appetite, regulates blood sugar, & promotes significant fat loss.

Glucagon-like peptide-1 receptor agonists show promise for reducing apnea-hypopnea index and body weight in patients with obstructive sleep apnea, offering new treatment options beyond PAP therapy.

The evidence base in support of the use of medicines based on glucagon-like peptide 1 beyond glucose control and weight loss was substantially bolstered in 2024, as clinical trial data report benefits of these medicines in people with a range of disorders.

However, current evidence does not prove cause and effect, and semaglutide is not approved to prevent or...